Indoor air purifiers remove ‘even nano-sized particles’
Recently incorporated UK-based company, KSG Health, has begun importing, and can now UK customers, a range of air purification devices from Finnish company, Genano.
Recently incorporated UK-based company, KSG Health, has begun importing and can now UK customers a range of air purification devices from Finnish company, Genano.
Genano says its ‘unique’ air purification method ‘removes even nano-sized particles up to 0.003 µm (3nm) in size from indoor air, eliminating microbes such as viruses, bacteria, and moulds, and also removing gases and odours’.
KSG Health said: “As an importer and distributor of Genano air purification devices in the UK, we have seen how this innovative technology allows building owners and managers to remove ultrafine particles effectively and efficiently and produce clinically clean air. Currently,” it continued, “healthcare authorities combating COVID-19 are upgrading their medical infrastructure due to traditional air purification methods not being sufficient to contain the microorganisms in the air. The commonly used fibre HEPA filters are deemed powerless against microbes under 0.3 µm in size, and unfortunately, the COVID-19 microbes are slightly larger than 0.1 µm in size.”
KSG Health says this means HEPA filtration-based air purification technologies are unable to remove ‘tiny, problematic particles’ – including pollution, microbes, bacteria, and viruses – ‘so there is a potential for these to remain in the recirculated air, be inhaled, and expose building users to serious illness’. It added: “Additionally, HEPA filters can become dirty from the collected particles, which reduces their air purification performance.”
In contrast, Genano technology is based on electronic filtration, meaning no contaminated residue left behind. KSG Health added: “A powerful ionisation process takes place within the chamber ,which is efficiently flushed out weekly without any reduction in performance. With no toxic waste, and minimal maintenance requirements, these units are efficient, cost-effective, and ideally suited to the indoor environment.”
Genano devices also incorporate an additional carbon filtration stage, which reportedly removes VOC gases. The technology is not, in fact new; it has been protecting the health and well-being of building occupants for 20 years, and KSG Health emphasises, is already installed in thousands of schools, hospitals, laboratories and offices worldwide.
Jarmo Kesanto, co-founder and co-director of KSG Health, who has worked with Genano business development since 2008, and built up the base of the UK business, explained: “Our well-established technology is ideally suited to meet the challenges posed by airborne viruses, and we are eager to see it utilised in all key settings to enhance the protection of vulnerable people. We hope that more organisations, including the NHS, will soon realise the benefits of replacing their current systems. Sadly, when it comes to nanosized particles such as SARS, MERS and COVID-19, the more limited HEPA-based systems are insufficient to remove these from the circulating air. At such a critical time, that may simply not be good enough.”